This document discusses several new and emerging therapies for HER2-positive advanced breast cancer. It summarizes clinical trial data showing that targeting HER2 remains effective after progression on trastuzumab. Several novel HER2-directed agents including pertuzumab, T-DM1, neratinib and afatinib are in late-stage clinical development and may be approved in the next 1-2 years. T-DM1 in particular combines the HER2-targeting of trastuzumab with a highly potent cytotoxic agent, and has shown promising antitumor activity with generally mild adverse events in clinical trials.
CNS metastases in Her2+ mBC: does size matter?Mauricio Lema
Sponsored by Roche.
There is a debate In pretreated Her2+ mBC as to whether the indisputable benefit of T-DM1 (an antibody drug conjugate anti Her2) over lapatinib (a small anti Her2 TKI) seen in the EMILIA trial also translates to CNS disease. The subgroup analysis of the EMILIA clearly shows that patients with CNS disease do not appear to have worse outcomes when treated with the big (T-DM1) as opposed to the small (lapatinib) drug.
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
CNS metastases in Her2+ mBC: does size matter?Mauricio Lema
Sponsored by Roche.
There is a debate In pretreated Her2+ mBC as to whether the indisputable benefit of T-DM1 (an antibody drug conjugate anti Her2) over lapatinib (a small anti Her2 TKI) seen in the EMILIA trial also translates to CNS disease. The subgroup analysis of the EMILIA clearly shows that patients with CNS disease do not appear to have worse outcomes when treated with the big (T-DM1) as opposed to the small (lapatinib) drug.
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
It is a PPT presentation talks about the magnitude of benefit from Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer. It will discuss briefly the most important clinical evidence in this setting. The aim of such work is to know how worthy is to give your patient Trastuzumab with her adjuvant chemotherapy in your clinical practice as a medical oncologist.
Michael Davies, MD, PhD discusses where we go from here in the melanoma field to conclude the 2017 MD Anderson Melanoma Patient Symposium held in Austin, TX on May 6, 2017.
What's the latest in breast cancer treatment and research? Erica Mayer, MD, MPH, a medical oncologist in the Susan F. Smith Center for Women's Cancers, shares the latest breast cancer news.
This presentation was originally given on Oct. 16, 2015, at the annual Young Women with Breast Cancer Forum, hosted by the Program for Young Women with Breast Cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Despite remarkable progress in the treatment of HER2+ breast cancer, management of this patient population continues to remain a challenge, both in the adjuvant and metastatic settings. An enhanced understanding of the treatment options available for HER2+ breast cancer patients in different settings is imperative to improving patient survival and quality of life. This activity consisting of didactic presentations and case illustrations will address treatment choices for HER2+ patients after trastuzumab progression; proposed mechanisms of resistance; combination treatment approaches; the role of anthracyclines and HER2-targeted agents in this population; and novel targeted agents under investigation, including mTOR inhibitors, antiangiogenic inhibitors, and HER2-targeted therapies.
More information:
http://imeronline.com/867dsd
Review a downloadable slide deck by Kathy D. Miller, MD, covering the most clinically relevant new data reported from Future Directions in the Treatment of Patients With HER2+ Breast Cancer: What Community Oncologists Need to Know.
Target Audience
This activity is designed to meet the educational needs of oncologists and other healthcare professionals involved in cancer care.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of September 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
More information:
http://imeronline.com/867dsd
Her2Neu positive breast cancer is comprises of about 15-20% of all breast cancer. Among them quite a few number of patients present as de novo metastasis . In this presentation you ll find a guide how to manage it with relevant evidences. Presentation is meant for Oncology trainees.
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
It is a PPT presentation talks about the magnitude of benefit from Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer. It will discuss briefly the most important clinical evidence in this setting. The aim of such work is to know how worthy is to give your patient Trastuzumab with her adjuvant chemotherapy in your clinical practice as a medical oncologist.
Michael Davies, MD, PhD discusses where we go from here in the melanoma field to conclude the 2017 MD Anderson Melanoma Patient Symposium held in Austin, TX on May 6, 2017.
What's the latest in breast cancer treatment and research? Erica Mayer, MD, MPH, a medical oncologist in the Susan F. Smith Center for Women's Cancers, shares the latest breast cancer news.
This presentation was originally given on Oct. 16, 2015, at the annual Young Women with Breast Cancer Forum, hosted by the Program for Young Women with Breast Cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Despite remarkable progress in the treatment of HER2+ breast cancer, management of this patient population continues to remain a challenge, both in the adjuvant and metastatic settings. An enhanced understanding of the treatment options available for HER2+ breast cancer patients in different settings is imperative to improving patient survival and quality of life. This activity consisting of didactic presentations and case illustrations will address treatment choices for HER2+ patients after trastuzumab progression; proposed mechanisms of resistance; combination treatment approaches; the role of anthracyclines and HER2-targeted agents in this population; and novel targeted agents under investigation, including mTOR inhibitors, antiangiogenic inhibitors, and HER2-targeted therapies.
More information:
http://imeronline.com/867dsd
Review a downloadable slide deck by Kathy D. Miller, MD, covering the most clinically relevant new data reported from Future Directions in the Treatment of Patients With HER2+ Breast Cancer: What Community Oncologists Need to Know.
Target Audience
This activity is designed to meet the educational needs of oncologists and other healthcare professionals involved in cancer care.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of September 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
More information:
http://imeronline.com/867dsd
Her2Neu positive breast cancer is comprises of about 15-20% of all breast cancer. Among them quite a few number of patients present as de novo metastasis . In this presentation you ll find a guide how to manage it with relevant evidences. Presentation is meant for Oncology trainees.
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
Learn about the process of radiation therapy to treat soft tissue sarcoma, and how new radiation technology has improved treatment of the disease.
This presentation was given by Elizabeth H. Baldini, MD, MPH, radiation oncology director for the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute. It was originally presented as part of the "15 Years of GIST/Soft Tissue Sarcoma Symposium," held on Sept. 12, 2015 at Dana-Farber in Boston, Mass.
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
Small Presentation where the benefit of addition of induction / neoadjuvant chemotherapy to concurrent chemoradiation in head neck cancers is explored.
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBCbkling
Dr. Virginia Kaklamani, Leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, will share her biggest takeaways from the latest research presented at the San Antonio Breast Cancer Symposium (SABCS) 2019 with a focus on metastatic breast cancer.
Similar to ABC1 - I.E. Krop, US - New and future therapies for HER-2+ advanced breast cancer (20)
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
ABC1 - I.E. Krop, US - New and future therapies for HER-2+ advanced breast cancer
1. New and future therapies for HER-2+ advanced breast cancer Ian Krop Dana-Farber Cancer Institute Harvard Medical School November 2011
2.
3.
4.
5.
6.
7. HER2:HER3 dimers may provide an escape mechanism from trastuzumab + + + + + + + + + + + Signaling activity + + + + Homodimers Heterodimers HER1:HER1 HER2:HER2 HER3:HER3 HER4:HER4 HER1:HER2 HER1:HER3 HER1:HER4 HER2:HER3 HER2:HER4 HER3:HER4 Tzahar, et al. Mol Cell Biol 1996. Sergina et al. Nature 2007, 445:437-441
8. Pertuzumab Activity 1. Baselga J et al. J Clin Oncol. 2010;28:1138-1144. 2. Cortés J et al. ASCO 2009 Annual Meeting. Abstract 1022. With Trastuzumab 1 n = 66 Monotherapy 2 n = 29 % % Best objective response CR 8 0 PR 17 7 SD-6 months 26 4 ORR 24 7 Clinical benefit rate 50 11
9. NeoSphere: Study Design THP (n=107) Docetaxel + Herceptin + Pertuzumab HP (n=107) Herceptin + Pertuzumab TP (n=96) Docetaxel + Pertuzumab S U R G E R Y Study dosing: q3w x 4 TH (n=107) Docetaxel + Herceptin Patients with operable or locally advanced /inflammatory* HER2-positive BC Chemo-naïve & primary tumours >2cm (N=417 ) BC, breast cancer; FEC, 5-fluorouracil, epirubicin and cyclophosphamide *Locally advanced=T2–3, N2–3, M0 or T4a–c, any N, M0; operable=T2–3, N0–1, M0; inflammatory = T4d, any N, M0 3 Docetaxel q3w x 4-> FEC q3w x 3 Herceptin q3w cycles 5–17 FEC q3w x 3 Herceptin q3w cycles 5–17 FEC q3w x 3 Herceptin q3w cycles 5–17 FEC q3w x 3 Herceptin q3w cycles 5–21
10. NeoSphere pCR Rates: ITT population summary pCR, % 95% CI Treatment 29.0% 45.8% 16.8% 24.0% 6 p = 0.0141 50 40 30 20 10 0 TH THP HP TP p = 0.0198 p = 0.003
11.
12.
13.
14.
15. T-DM1 selectively delivers DM1 to HER2-positive tumor cells Receptor-T-DM1 complex is internalized into HER2-positive cancer cell Potent antimicrotubule agent is released once inside the HER2-positive tumor cell T-DM1 binds to the HER2 protein on cancer cells HER2
24. Platelet counts at the MTD: consistent effects over time Platelet count by study day for 3.6 mg/kg cohort T – DM1 administered on Day 21 of each cycle. Krop et al, JCO 2010:2698
25. Patterns of thrombocytopenia with T-DM1 Stable effects over time ≈ 80% of patients Cumulative loss of platelets ≈ 20% of patients Bender et al, SABCS 2010
26.
27.
28. Objective Response by Investigator Patients With Measurable Disease at Baseline a One patient was not included in the efficacy analysis due to study site withdrawal. b Defined as complete or partial response based on RECIST 1.0 determined on 2 consecutive tumor assessments at least 4 weeks apart. c Defined as objective response any time during the study or maintained stable disease for at least 6 months from randomization. Hurvitz et al, ESMO 2011 Trastuzumab + docetaxel (n=69) a T-DM1 (n=67) Patients with an objective response, b n (%) 40 (58.0) 43 (64.2) 95% CI 45.5–69.2 51.8–74.8 Objective responses, n (%) Complete response 3 (4.3) 7 (10.4) Partial response 37 (53.6) 36 (53.7) Stable disease 23 (33.3) 13 (19.4) Progressive disease 4 (5.8) 8 (11.9) Unable to evaluate or missing 2 (2.9) 3 (4.5) Patients with clinical benefit, c n (%) 56 (81.2) 50 (74.6) 95% CI 70.7–89.1 63.2–84.2
29. Time (months) Proportion progression-free 1.0 0.8 0.6 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 Number of patients at risk T+D 70 66 63 53 43 27 12 4 2 2 0 T-DM1 67 60 51 46 42 35 22 15 6 3 0 Trastuzumab + docetaxel (n=70) T-DM1 (n=67) Progression-Free Survival by Investigator Randomized Patients Median PFS, mos Hazard ratio 95% CI Log-rank P value 9.2 14.2 0.594 0.364– 0.968 0.0353
30. Duration of objective response (months) Proportion progression-free Number of patients at risk T+D 40 40 38 32 19 8 2 1 1 0 T-DM1 43 41 38 33 27 19 12 6 3 0 0 2 4 6 8 10 12 14 16 18 1.0 0.8 0.6 0.4 0.2 0.0 Trastuzumab + docetaxel (n=40) T-DM1 (n=43) Duration of Response by Investigator Patients with Measurable Disease at Baseline with an Objective Response Median DOR, mos 95% CI 9.5 NR 6.6–10.6 –
31. Summary of Adverse Events Safety Evaluable Patients a Two patients mistakenly received a dose of T-DM1 and were thus included in the T-DM1 arm for safety analyses. b Includes 3 patients who received at least 1 dose of trastuzumab alone or trastuzumab plus docetaxel. c Due to cardiopulmonary failure. d Due to sudden death. Hurvitz et al, ESMO 2011 No clinically significant cardiac events reported Trastuzumab + docetaxel (n=66) a , n (%) T-DM1 (n=69) a,b , n (%) Any grade ≥3 AE 59 (89.4) 32 (46.4) AE leading to discontinuation of any study treatment component (any grade) 19 (28.8) 5 (7.2) AE leading to death 1 (1.5) c 1 (1.4) d Serious AEs (any grade) 17 (25.8) 13 (18.8)
32.
33.
34.
35. Th3RESA: Study Schema Study treatment continues until disease progression or unmanageable toxicity HER2 positive (Centrally confirmed) Unresectable locally advanced/recurrent or Metastatic breast cancer Prior trastuzumab, lapatinib, anthracycline, taxane, and capecitabine Treatment of physician ’ s choice N = 795 2:1 randomization 2 1 T-DM1 q3w
39. NeoALTTO: Pathologic CR Rates Baselga J et al. SABCS 2010. Abstract S3-3. No difference in proportion of patients undergoing breast conservation Path CR (Breast Only) Path CR (Breast and LN) Lapatinib + Paclitaxel 25% 20% Trastuzumab + Paclitaxel 29% 28% Trastuzumab + Lapatinib + Paclitaxel 51% 47%
40. Lapatinib +/- Trastuzumab in HER2+ MBC Progressing on Trastuzumab: Updated Overall Survival in ITT Blackwell KL et al. J Clin Oncol . 2010;28:1124. Time From Random Assignment (weeks) Patients at Risk L + T 148 L 148 106 121 30 40 3 4 L N = 145 L+T N = 146 Died, n 69 56 Median, wk 39.0 51.6 Hazard ratio (95% CI) 0.75 (0.53, 1.07) P value 0.106 Survival (%) L + T L 100 80 60 40 20 0 0 20 60 40 80 45 70 36 6 Months OS 12 Months OS
41. Trastuzumab+lapatinib in HER2+ MBC Lin et al. ASCO 2011 Best Overall Response (n=76) Response 1 st Line (n=36) N (%) 2 nd /3 rd line (n=40) N (%) Confirmed response Complete response Partial response 16 (44%) 3 13 9 (23%) 0 9 Unconfirmed response Complete response Partial response 3 (8%) 0 3 5 (13%) 0 5 Stable disease 5 (14%) 16 (40%) Progressive disease 10 (28%) 10 (25%) Unknown 2 (6%) 0 (0%) Clinical Benefit Rate (confirmed CR or PR + SD > 24 weeks) 17 (47%) 14 (35%)
42.
Editor's Notes
Add isakoff slide for pertuz Find # of priors for pertuz Find exposure data for tdm1 weekly
by selectively delivering drugs to overexpressed antigens on tumor cells than could be achieved by administration of either antibody or chemotherapy as free agents
T-DM1 Mechanism of Action T-DM1 is a unique ADC because it provides intracellular delivery of the highly potent cytotoxic agent DM1 to HER2-overexpressing cells, in addition to the antitumor activities of trastuzumab. Trastuzumab biological activity is retained by T-DM1; trastuzumab MOAs include: Antibody-dependent cellular cytotoxicity (ADCC) Inhibition of cell signaling through the PI3K/AKT pathway Inhibition of HER2 shedding • It is thought that once T-DM1 binds HER2, the receptor–ADC complex is internalized, then degraded by proteolytic digestion in lysosomes. This allows for the release of DM1 into the cytoplasm and the subsequent inhibition of microtubule assembly, resulting in cell death DM1 is a highly potent microtubule inhibitor 20-100 times more potent than vincristine and 25-500 fold more potent than paclitaxel in cytotoxic assays
.
“ A novel exploitation of HER2 biology” The green fluorophore Alexa-488 was conjugated to trastuzumab BT474 cells incubated with 488trastuzumab +/- were incubated 1 micromolar GA for 3h and then imaged by fluorescence microscopy
Thrombocytopenia at the MTD (3.6 mg/kg) was generally Grade ≤ 1 and non-cumulative, without significant lowering of nadirs or increase in time to recovery after repeated administration. 1 Platelet nadirs were observed on approximately Day 8; recovery was rapid (by approximately Day 15). Reference Krop IE, Beeram M, Modi S, Rabbee N, Girish S, Tibbitts J, et al. A Phase I study of trastuzumab – DM1, a first-in-class HER2 antibody – drug conjugate (ADC), in patients with HER2+ metastatic breast cancer. San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 13–16, 2007 (Abstract 310).
In the T-DM1 arm dose delays (up to 3 weeks) and dose reductions (3.0 mg/kg and 2.4 mg/kg) may occur for toxicity. In the trastuzumab-plus-docetaxel arm standard dose modifications apply Patients in the trastuzumab-plus-docetaxel arm may crossover to T-DM1 therapy upon radiographic progression. All patients will be followed for subsequent therapy until death. Reference A study of the efficacy and safety of T-DM1 vs. trastuzumab (Herceptin ® ) and docetaxel (Taxotere ® ) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease. ClinicalTrials.gov [Website]. http://www.clinicaltrials.gov/ct2/show/NCT00679341?term=T-DM1+docetaxel&rank=1. Updated October 9, 2009. Accessed October 22, 2009.
Secondary Endpoints: ORR by investigator were very similar between control arm and experimental T-DM1 arm Stable disease includes 11 patients with unconfirmed partial response (5 in T-DM1 arm and 6 in the trastuzumab + docetaxel arm) QOL data to be presented at a future congress (SABCS) QOL Background: Trial Outcome Index–Physical/Functional/Breast (TOI-PFB) subset of the Functional Assessment of Cancer Therapy Breast (FACT-B) provides a summary measure of physical and functional well-being and breast cancer–specific symptoms. QOL analyses were based on patients who had a FACT-B assessment at cycle 1 and at least one FACT-B assessment after cycle 1; a change of 5 points in the FACT-B TOI-PFB is considered clinically meaningful, which may reflect changes of QOL due to treatment side effects and/or disease burden. The worsening of health-related QOL, as measured by the first 5 points drop from baseline for TOI-PFB, was significantly delayed in patients treated with T-DM1 relative to patients treated with docetaxel plus trastuzumab. RECIST, Response Evaluation Criteria In Solid Tumors.
Clear differences were seen between study arms in terms of Grade 3 or greater AEs (89% for control arm vs. 46% for T-DM1) AEs led to treatment discontinuation more frequently in the control arm than T-DM1 arm Serious AEs were numerically more common in control arm Note that the discontinuation for AE any drug for control arm means that any treatment had to be stopped (docetaxel) due to AE. Therefore 28.8% is higher than the 5.7% seen in disposition slide because both docetaxel and trastuzumab were discontinued for those AEs. AEs leading to death (1 each on control and experimental T-DM1 arm were not attributed to study treatment by investigator ) Death on T-DM1: this is the event of sudden death occurred after one dose of T-DM1 due to medication error. However, this pt had episodes of syncope while on trastuzumab + docetaxel (prior to the dose of T-DM1) and the etiology of syncope was being investigated prior to the event (without conclusions). Death on trastuzumab + docetaxel: this pt had Grade 5 ACUTE cardiopumonary FAILURE; right before this reported event, pt experienced DVT, A-fib, and renal failure. Pt also had history of HTN, ISCHAEMIC HEART DISEASE, and aortic insufficiency. AE, adverse event Serious AEs = AEs that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability/incapacity, or are congenital anomalies/birth defects
In the T - DM1 arm dose delays and reductions are allowed per protocol toxicity guidelines. In the control arm (lapatinib + capecitabine), dosing modifications are by prescribing guidelines. All patients will be followed with tumor assessments until progression and for subsequent therapy until death. Independent committees: data monitoring committee are to monitor overall safety data; cardiac review committee to review potential cases of left ventricular systolic dysfunction. Reference An open-label study of trastuzumab-MCC-DM1 (T-DM1) vs. capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer. ClinicalTrials.gov [Website]. http://www.clinicaltrials.gov/ct2/show/NCT00829166? term=T-DM1&rank=2. Updated October 5, 2009. Accessed October 23, 2009 .
No crossover allowed for control arm to T-DM1 after PD (OS)